Jakob Benedict Seidelin

Jakob Benedict Seidelin

Clinical Professor

Member of:

  • Internal Medicine: Gastroenterology and Hepatology


  1. Published

    Prediction of Relapse After Anti–Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies

    Pauwels, R. W. M., van der Woude, C. J., Nieboer, D., Steyerberg, E. W., Casanova, M. J., Gisbert, J. P., Kennedy, N. A., Lees, C. W., Louis, E., Molnár, T., Szántó, K., Leo, E., Bots, S., Downey, R., Lukas, M., Lin, W. C., Amiot, A., Lu, C., Roblin, X., Farkas, K. & 15 others, Seidelin, Jakob Benedict, Duijvestein, M., D'Haens, G. R., de Vries, A. C., Janneke van der Woude, C., Sleutjes, J. A. M., García-Ortiz, J. M., Brooks, A. J., Hamlin, P. J., Sebastian, S., Lobo, A. J., Dieleman, L. (. A., Ben-Horin, S., Steenholdt, Casper & CEASE Study Group, C. S. G., 2022, In: Clinical Gastroenterology and Hepatology. 20, 8, p. 1671-1686.e16

    Research output: Contribution to journalReviewResearchpeer-review

  2. Published

    Predictors of response and disease course in patients with inflammatory bowel disease treated with biological therapy - The Danish IBD Biobank Project: protocol for a multicentre prospective cohort study

    Zhao, M., Bendtsen, Flemming, Petersen, Andreas Munk, Larsen, L., Dige, A., Hvas, C., Seidelin, Jakob Benedict & Burisch, J., 2020, In: BMJ Open. 10, 2, 7 p., e035756.

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Published

    Prevalence and outcomes of COVID-19 among patients with inflammatory bowel disease: A Danish prospective population-based cohort study

    Attauabi, M., Poulsen, A., Theede, K., Pedersen, N., Larsen, L., Jess, T., Rosager Hansen, M., Kajbæk Verner-Andersen, M., V Haderslev, K., Berg Lødrup, A., Molazahi, A., Neumann, A., Wase, A., Seidelin, Jakob Benedict & Burisch, J., 2021, In: Journal of Crohn's and Colitis. 15, 4, p. 540–550

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Published

    Primary monocytes derived from ulcerative colitis show no difference in the TNF-alpha-induced immune response among responders and primary non-responders to infliximab

    Li, Y., Jensen, Kim Bak, Seidelin, Jakob Benedict & Nielsen, O. H., Sep 2017, In: Journal of Gastroenterology and Hepatology. 32, S3, p. 138-138 P-0750.

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  5. Published

    Putative biomarkers of vedolizumab resistance and underlying inflammatory pathways involved in IBD

    Soendergaard, C., Seidelin, Jakob Benedict, Steenholdt, C. & Nielsen, Ole Haagen, 2018, In: B M J Open Gastroenterology. 5, 1, e000208.

    Research output: Contribution to journalJournal articleResearchpeer-review

  6. Published

    Recent therapeutic advances in inflammatory bowel disease

    Nielsen, Ole Haagen, Nielsen, S. E. & Seidelin, Jakob Benedict, Jul 2002, In: I Drugs: the Investigational Drugs Journal. 5, 7, p. 618-22 5 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  7. Published

    Regulation of antiapoptotic and cytoprotective pathways in colonic epithelial cells in ulcerative colitis

    Seidelin, Jakob Benedict, 2015, In: Scandinavian Journal of Gastroenterology. 50 , Suppl 1, p. 1-29 29 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  8. Published

    Regulering af cytokindannelse ved inflammatoriske tarmsygdomme

    Ferrero-Miliani, L., Seidelin, Jakob Benedict & Nielsen, Ole Haagen, 8 May 2006, In: Ugeskrift for Laeger. 168, 19, p. 1847-50 4 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  9. Published

    Relation between NOD2 genotype and changes in innate signaling in Crohn's disease on mRNA and miRNA levels

    Chen, Y., Salem, M., Boyd, M., Lange, Jette Bornholdt, Li, Yuan, Coskun, M., Seidelin, Jakob Benedict, Sandelin, Albin Gustav & Nielsen, Ole Haagen, 2017, In: npj Genomic Medicine. 2, 11 p., 3.

    Research output: Contribution to journalJournal articleResearchpeer-review

  10. Published

    Reply to comment on: "Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis"

    Attauabi, M., Seidelin, Jakob Benedict & Burisch, J., 2023, In: Rendiconti di Gastro-Enterologia. 55, 2, p. 300-301

    Research output: Contribution to journalComment/debateResearchpeer-review

ID: 33971112